This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...

Investor attention is shifting toward a key scientific conference as shares of biotechnology firm Veru Inc. trade quietly. The company is scheduled to deliver multiple presentations on its lead drug ...

Che-Kai Tsao, MD, MS, system chief of Solid Tumor Oncology at Northwell Health Cancer Institute, discusses new approaches ...

Certain men face a far greater risk of prostate cancer – yet many will still not be routinely offered testing under new ...

Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...